We O
show O
that O
1 O
, O
25-dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B
RNA I
accumulation O
of O
the O
multilineage O
growth O
factor O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
. O

OBJECTIVE O
: O
To O
identify O
and O
characterize O
estrogen B
receptor I
( I
ER I
) I
transcripts I
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

These O
cells O
were O
examined O
for O
ER B
mRNA I
by O
reverse O
transcription O
nested O
polymerase O
chain O
reaction O
. O

RESULTS O
: O
In O
all O
cells O
tested O
, O
ER B
mRNA I
was O
expressed O
without O
prior O
in O
vitro O
stimulation O
. O

Partial O
sequences O
from O
exons O
1-8 O
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human B
ER I
mRNA I
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B
transcripts I
between O
patients O
and O
healthy O
controls O
. O

In O
vitro O
stimulation O
did O
not O
affect O
ER B
mRNA I
expression O
. O

Minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML/RAR O
alpha O
or O
AML1/ETO B
mRNA I
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

Using O
the O
reverse O
transcription-polymerase O
chain O
reaction O
( O
RT O
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
-5 O
) O
to O
10 O
( O
-6 O
) O
for O
PML/RAR B
alpha I
transcript I
and O
10 O
( O
-4 O
) O
to O
10 O
( O
-5 O
) O
for O
the O
AML1/ETO B
transcript I
. O

Appropriate O
sized O
transcripts B
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A O
, O
CYP17 O
, O
HSD11L O
( O
11beta-hydroxysteroid O
dehydrogenase O
I O
) O
, O
HSD17B1 O
( O
17beta-hydroxysteroid O
dehydrogenase O
type O
I O
) O
and O
SRD5A1 O
( O
5alpha-reductase O
I O
) O
. O

Human O
white O
blood O
cells O
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA B
for O
the O
pterin O
carbinolamine O
dehydratase/dimerization O
cofactor O
of O
HNF1 O
for O
mutation O
detection O
. O

Here O
we O
report O
for O
the O
first O
time O
that O
the O
PCD/DCoH B
mRNA I
is O
present O
in O
human O
white O
blood O
cells O
and O
hair O
follicles O
. O

A O
5.4-kilobase B
mRNA I
, O
the O
expression O
of O
which O
is O
down-regulated O
after O
treatment O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
various O
T O
cell-activating O
agents O
, O
was O
isolated O
using O
an O
mRNA O
differential O
display O
method O
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 B
' I
end I
of O
this O
RNA B
as O
human B
retinoid I
receptor I
RXRalpha I
mRNA I
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3.6 O
kilobases O
of O
this O
RNA O
, O
which O
represents O
the O
3 B
' I
end I
of O
RXRalpha B
mRNA I
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

Activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha O
protein O
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation-induced O
loss O
of O
RXRalpha B
mRNA I
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O

The O
decrease O
in O
the O
levels O
of O
RXRalpha B
mRNA I
was O
found O
to O
be O
regulated O
at O
the O
post-transcriptional O
level O
and O
involved O
new O
protein O
synthesis O
. O

MPs O
and O
HeLa O
cells O
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue B
factor I
transcripts I
( O
approximately O
18-fold O
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15-fold O
) O
, O
based O
on O
nuclear O
run-on O
analysis O
. O

Anti-CD3-restimulated O
T O
cells O
( O
mainly O
CD8+ O
) O
produced O
IL-2 O
, O
interferon-gamma O
( O
IFN-gamma O
) O
and O
tumour O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
and O
low O
levels O
of O
IL-4 B
and I
IL-10 I
transcripts I
and O
proteins O
. O

The O
kinetics O
of O
TNF-alpha B
mRNA I
expression O
was O
faster O
, O
being O
at O
its O
peak O
level O
1 O
hr O
after O
stimulation O
. O

The O
CRABP B
II I
mRNA I
was O
gradually O
upregulated O
during O
differentiation O
from O
MO O
to O
MAC O
in O
the O
presence O
of O
2 O
% O
serum O
. O

Northern O
blot O
analysis O
showed O
that O
LPS-induced O
expression O
of O
these O
cytokine B
mRNA I
in O
monocytes O
was O
suppressed O
by O
CS O
. O

These O
findings O
indicate O
that O
CS O
has O
a O
suppressive O
effect O
on O
proinflammatory O
cytokine O
production O
from O
monocytes O
, O
and O
this O
effect O
is O
based O
in O
part O
on O
the O
suppression O
of O
cytokine B
mRNA I
expression O
through O
inhibition O
of O
NF-kappaB O
activation O
. O

Elevated O
expression O
of O
differentiation B
inhibitory I
factor I
nm23 I
mRNA I
in O
monoblastic O
crisis O
of O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
. O

We O
report O
an O
example O
of O
elevated O
expression O
of O
nm23 B
mRNA I
in O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
( O
CML O
) O
who O
developed O
monoblastic O
crisis O
. O

Relative O
levels O
of O
nm23-H1 B
and I
-H2 I
mRNA I
extracted O
from O
the O
patient O
's O
peripheral O
blood O
mononuclear O
cells O
and O
bone O
marrow O
mononuclear O
cells O
were O
measured O
by O
quantitative O
reverse O
transcriptase O
polymerase O
chain O
reaction O
. O

The O
level O
of O
nm23-H1 B
mRNA I
in O
CML O
cells O
at O
the O
chronic O
phase O
was O
as O
high O
as O
that O
in O
bone O
marrow O
cells O
from O
healthy O
volunteers O
. O

At O
blastic O
crisis O
, O
however O
, O
expression O
of O
both O
nm23-H1 B
and I
-H2 I
mRNA I
was O
elevated O
to O
about O
three O
to O
nine O
times O
of O
that O
at O
the O
chronic O
phase O
. O

Tk B
mRNA I
is O
induced O
following O
treatment O
with O
estrogen O
. O

Stimulation O
with O
GM-CSF O
enhanced O
c-myb B
mRNA I
expression O
in O
these O
cells O
. O

Hypoxia O
down-regulated O
TNF-alpha-induced B
MCP-1 I
mRNA I
and O
protein O
production O
by O
ovarian O
cancer O
cells O
. O

Protein O
kinase O
C O
( O
PKC O
) O
has O
been O
suggested O
to O
regulate O
PMA-induced O
adhesion O
molecule O
expression O
by O
post-transcriptional O
stabilization O
of O
adhesion B
molecule I
mRNA I
. O

To O
assess O
HUVEC O
activation O
, O
E-selectin O
expression O
was O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E-selectin-specific B
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF-kappa O
B O
, O
a O
transcription O
factor O
necessary O
for O
E-selectin O
gene O
activation O
. O

B. O
fragilis O
outer O
membranes O
induced O
translocation O
of O
NF-kappa O
B O
to O
HUVEC O
nuclei O
and O
accumulation O
of O
E-selectin B
mRNA I
in O
HUVEC O
cytoplasm O
. O

Mechanical O
strains O
induced O
SRA B
mRNA I
( O
3.5+/-0.6-fold O
at O
3 O
% O
strain O
for O
48 O
hours O
, O
P O
< O
0.01 O
) O
and O
SRA O
protein O
in O
THP-1 O
cells O
in O
an O
amplitude-dependent O
manner O
. O

RESULTS O
: O
Glucose O
induced O
MCP-1 B
mRNA I
expression O
in O
a O
time- O
and O
dose-dependent O
manner O
. O

Curcumin O
, O
an O
inhibitor O
of O
AP-1 O
, O
dose-dependently O
suppressed O
the O
induction O
of O
MCP-1 B
mRNA I
by O
high O
glucose O
. O

Tyrosine O
kinase O
inhibitors O
such O
as O
genistein O
( O
12.5 O
to O
50 O
micromol/L O
) O
and O
herbimycin O
A O
( O
0.1 O
to O
1 O
micromol/L O
) O
inhibited O
the O
high-glucose-induced O
MCP-1 B
mRNA I
expression O
in O
a O
dose-dependent O
manner O
, O
and O
also O
suppressed O
the O
high-glucose-induced O
AP-1 O
binding O
activity O
. O

TNF-alpha B
mRNA I
was O
measured O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
, O
and O
NF-kappaB O
DNA O
binding O
activity O
was O
assessed O
by O
gel O
mobility O
shift O
assay O
. O

Neither O
TNF-alpha B
mRNA I
expression O
nor O
NF-kappaB O
activation O
stimulated O
by O
LPS O
was O
inhibited O
by O
the O
cAMP-elevating O
agents O
. O

We O
identified O
PPAR-alpha B
and I
-gamma I
messenger O
RNA O
by O
RT-PCR O
and O
protein O
by O
immunoblotting O
of O
lysates O
of O
peritoneal O
macrophages O
and O
monocytic O
U937 O
cells O
. O

Furthermore O
, O
in O
immunized O
mice O
, O
OBF-1 O
protein O
amounts O
are O
dramatically O
increased O
in O
primary O
activated O
B O
cells O
, O
without O
concomitant O
increase O
in O
OBF-1 B
mRNA I
. O

Biopsies O
were O
immunostained O
for O
inflammatory O
cell O
markers O
as O
well O
as O
GRbeta O
and O
probed O
for O
various O
cytokine B
mRNA I
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome O
proliferator-activated O
receptor-gamma O
( O
PPARgamma O
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma O
agonists O
like O
15d-PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma O
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA-D O
genes O
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B
( I
class I
II I
transactivator I
) I
transcripts I
, O
CIITA O
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

One O
of O
the O
most O
prominent O
glucocorticoid-induced O
genes O
is O
glucocorticoid-induced O
leucine O
zipper O
( O
GILZ O
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation-induced O
up-regulation O
of O
Fas B
ligand I
( I
FasL I
) I
mRNA I
. O

First O
, O
we O
found O
that O
TGF-beta1 O
significantly O
increases O
endogenous B
germ-line I
( I
GL I
) I
alpha I
transcripts I
by O
LPS-stimulated O
CH12.LX.4933 O
( O
mu O
( O
+ O
) O
) O
B O
lymphoma O
cells O
. O

Similar O
to O
endogenous B
GLalpha I
transcripts I
, O
TGF-beta1 O
induces O
GLalpha O
promoter O
activity O
and O
overexpression O
of O
Smad3 O
markedly O
enhances O
the O
promoter O
activity O
. O

In O
addition O
, O
overexpression O
of O
Smad3/4 O
enhances O
TGF-beta1 O
-induced O
endogenous B
GLalpha I
transcripts I
in O
normal O
spleen O
B O
cell O
s O
. O

Blockade O
of O
depletion O
of O
IkappaB-alpha O
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I O
or O
acetyl-leucinyl-leucinyl-norleucinal O
) O
led O
to O
concomitant O
inhibition O
of O
NF-kappaB O
DNA-binding O
activity O
and O
expression O
of O
MIP-1alpha B
and I
MIP-1beta I
messenger I
RNA I
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O

Interferon-gamma O
( O
IFN-gamma O
) O
, O
a O
cytokine O
that O
exerts O
many O
pro-atherosclerotic O
effects O
in O
vivo O
, O
causes O
up-regulation O
of O
ACAT-1 B
mRNA I
in O
human O
blood O
monocyte-derived O
macrophages O
and O
macrophage-like O
cells O
but O
not O
in O
other O
cell O
types O
. O

NF-kappaB O
and O
activator O
protein-1 O
( O
AP-1 O
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin-6 B
, O
tumor O
necrosis O
factor-alpha O
, O
KC O
, O
monocyte O
chemoattractant O
protein-1 O
, O
and O
inducible O
nitric O
oxide O
synthase O
was O
assessed O
by O
semiquantitative O
RT-PCR O
. O

Morphological O
damage O
and O
trypsin O
activation O
were O
much O
greater O
in O
the O
pancreatic O
head O
than O
tail O
, O
in O
parallel O
with O
a O
stronger O
activation O
of O
NF-kappaB B
and I
cytokine I
mRNA I
. O

Using O
RT-PCR O
, O
we O
found O
that O
CD45R0 O
signaling O
inhibited O
IL-2 O
mRNA O
production O
without O
major O
influence O
on O
IL-13 O
, O
IL-5 O
, O
or O
IFN-gamma B
mRNA I
levels O
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant O
gp350 O
( O
rgp350 O
) O
and O
EBV O
upregulate O
IL-6 B
mRNA I
synthesis O
in O
B O
cells O
, O
EBV-induced O
IL-6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i.e. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 O
) O
. O

Moreover O
, O
the O
half-life O
of O
EBV-induced O
IL-6 B
mRNA I
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA O
induced O
by O
rgp350 O
( O
about O
6 O
hours O
) O
. O

METHODS O
: O
Cord O
blood O
mononuclear O
cells O
were O
Th1- O
or O
Th2-polarized O
by O
culture O
in O
IL-12- O
or O
IL-4-employing O
established O
methods O
; O
PBMC O
from O
house O
dust O
mite O
( O
HDM O
) O
-sensitive O
atopics O
and O
controls O
were O
stimulated O
overnight O
with O
HDM O
; O
cytokine O
production O
was O
measured O
by O
ELISA O
and O
GATA-3 B
mRNA I
expression O
by O
PCR O
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV-DNA O
, O
EBV-encoded B
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV-DNA O
fragments O
containing O
the O
terminal O
repeats O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
-1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q O
promoter O
, O
whereas O
both O
the O
Q O
promoter O
and O
another O
upstream O
promoter O
( O
Cp/Wp O
) O
were O
used O
in O
EBV-positive O
cell O
lines O
, O
B95.8 O
, O
Raji O
and O
Jiyoye O
. O

Latent B
membrane I
protein-1 I
( I
LMP-1 I
) I
mRNA I
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell O
lines O
, O
whereas O
EBNA-2 B
transcripts I
were O
found O
only O
in O
the O
cell O
lines O
. O

Latent B
BHRF1 I
transcripts I
encoding O
bcl-2 B
homologue I
and O
BCRF1 B
transcripts I
encoding O
viral O
interleukin O
( O
vIL O
) O
-10 O
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

Our O
results O
indicate O
that O
the O
restricted O
expression O
of O
the O
latency-associated O
EBV O
genes O
and O
the O
production O
of O
vIL-10 B
and I
bcl-2 I
homologue I
may O
favour O
tumour O
growth O
, O
evading O
the O
host O
immune O
surveillance O
. O

We O
demonstrate O
that O
both O
naive O
and O
activated O
ovalbumin-specific O
T O
cells O
from O
DO11.10-transgenic O
mice O
express O
PPAR-gamma B
mRNA O
and O
protein O
. O

Culture O
with O
the O
murine O
fetal O
liver O
cell O
line O
AFT024 O
and O
defined O
cytokines O
was O
capable O
of O
inducing O
TCF-1 B
mRNA I
. O

Whereas O
expression O
of O
E2A O
mRNA O
and O
protein O
are O
unaltered O
, O
Id3 B
transcripts I
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR O
. O

Investigation O
of O
retinoid O
receptor O
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR B
alpha I
, I
RAR I
gamma I
, I
RXR I
beta I
, I
and I
RXR I
gamma I
transcripts I
in O
all O
cell O
lines O
studied O
, O
and O
HMC-1 O
cells O
were O
the O
only O
line O
lacking O
RXR O
alpha O
. O

During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta B
mRNA I
, O
while O
the O
RXR O
had O
no O
effect O
. O

UTI O
decreased O
the O
TNFalpha O
production O
of O
LPS-stimulated O
monocytes O
, O
but O
did O
not O
inhibit O
the O
TNFalpha B
mRNA I
expression O
. O

Such O
effect O
was O
accompanied O
by O
an O
increased O
expression O
of O
MCP-1 B
mRNA I
( O
176 O
% O
as O
compared O
to O
the O
control O
) O
in O
endothelial O
cells O
which O
resulted O
in O
enhanced O
monocyte O
chemotaxis O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL-1-dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines O
monocyte O
chemoattractant O
protein O
1 O
, O
macrophage O
inhibitory O
protein O
2 O
( O
MIP-2 O
) O
, O
RANTES O
, O
MIP-1alpha O
, O
and O
MIP-1beta O
, O
in O
vivo O
and O
in O
vitro O
. O

Notably O
, O
the O
protein O
kinase O
C O
inhibitors O
calphostin O
C O
and O
staurosporine O
reduced O
high O
glucose- O
or O
high O
mannitol-induced O
intercellular B
adhesion I
molecule-1 I
mRNA O
expression O
and O
high O
glucose-induced O
proliferation O
. O

Furthermore O
, O
the O
NF-kappa O
B O
inhibitor O
N-tosyl-L-phenylalanine O
chloromethyl O
ketone O
reduced O
high O
glucose- O
or O
high O
mannitol-induced O
intercellular B
adhesion I
molecule-1 I
mRNA O
expression O
and O
high O
glucose-induced O
proliferation O
. O

Transcripts O
to O
RAR-alpha B
, O
RAR-beta B
and O
RXR-alpha B
increased O
after O
incubation O
with O
9-cRA O
whereas O
RXR-gamma B
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs O
and O
RXRs O
in O
9-cRA-anti-inflammatory O
effects O
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon O
receptor O
( O
AHR O
) O
, O
a O
member O
of O
the O
bHLH-PAS O
family O
of O
transcription O
factors O
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL-2 B
in O
murine O
fetal O
thymocytes O
. O

Thus O
, O
the O
induction O
of O
AP-1 B
mRNA I
by O
Tax O
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP-1 O
site O
by O
Tax O
. O

Normal O
mouse O
B O
cells O
and O
a O
variety O
of O
B O
lymphoma O
cells O
reflective O
of O
stages O
of O
B O
cell O
differentiation O
( O
e.g. O
, O
70Z/3 O
, O
CH31 O
, O
WEHI-231 O
, O
CH12 O
, O
and O
J558 O
) O
express O
PPAR-gamma B
mRNA I
and O
, O
by O
Western O
blot O
analysis O
, O
the O
67-kDa O
PPAR-gamma O
protein O
. O

NFAT O
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA-binding O
assays O
, O
and O
RT-PCR O
analysis O
of O
eosinophil B
mRNA I
. O

In O
addition O
, O
eosinophils O
were O
found O
to O
constitutively O
express O
NFATc B
mRNA I
. O

Using O
a O
rat O
model O
of O
acute O
lung O
inflammation O
induced O
by O
intratracheal O
instillation O
of O
sodium O
metavanadate O
( O
NaVO3 O
) O
at O
the O
dose O
of O
200 O
microg O
V/kg O
, O
we O
investigated O
the O
relationship O
between O
the O
cytologic O
characterization O
of O
pulmonary O
inflammation O
and O
the O
expression O
of O
chemokine B
mRNA I
. O

By O
Northern O
analysis O
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
-2 I
mRNA I
in O
BAL O
cells O
increased O
markedly O
1 O
h O
after O
NaVO3 O
instillation O
and O
reduced O
a O
little O
bit O
at O
4 O
h O
, O
whereas O
MIP-1alpha B
mRNA I
in O
BAL O
cells O
was O
expressed O
relatively O
high O
1 O
h O
after O
NaVO3 O
instillation O
, O
although O
a O
basal O
expression O
was O
detected O
in O
control O
group O
, O
and O
returned O
rapidly O
nearly O
to O
control O
level O
at O
4 O
h O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP-2 O
mRNA O
expression O
, O
suggesting O
that O
MIP-2 O
is O
involved O
in O
the O
development O
of O
NaVO3-induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP-1alpha B
mRNA I
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP-1alpha O
, O
adherent O
to O
the O
lining O
surface O
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF-kappaB O
, O
not O
AP-1 O
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP-2 B
mRNA I
. O

In O
addition O
, O
elevated O
MIP-2 B
mRNA I
levels O
are O
accompanied O
by O
increased O
NF-kappaB O
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP-2 O
transcriptional O
regulation O
through O
NF-kappaB O
. O

In O
this O
study O
we O
analysed O
the O
induction O
of O
factors O
involved O
in O
cytokine O
signal O
transduction O
, O
such O
as O
STAT O
1 O
proteins O
and O
IRF-1 B
mRNA I
, O
in O
normal O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
exposed O
to O
HIV-infected O
cells O
, O
and O
the O
induction O
of O
apoptosis O
. O

Western O
blot O
analyses O
and O
reverse O
transcriptase-polymerase O
chain O
reaction O
results O
indicate O
that O
both O
cells O
infected O
with O
a O
X4 O
strain O
and O
cells O
infected O
with O
a O
R5 O
strain O
are O
able O
to O
increase O
intracellular O
levels O
of O
STAT O
1alpha O
and O
beta O
proteins O
as O
well O
as O
IRF-1 B
mRNA I
. O

HIV-1-infected O
cells O
dose-dependently O
induced O
apoptotic O
commitment O
in O
normal O
PBMC O
, O
as O
revealed O
by O
DNA O
fragmentation O
analysis O
, O
but O
this O
was O
not O
accompanied O
by O
an O
increase O
of O
caspase-3 O
activity O
, O
even O
if O
a O
slight O
up-regulation O
of O
IL-1beta-converting B
enzyme I
mRNA I
was O
detected O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax O
can O
activate O
transcription O
through O
the O
AP-1-binding O
site O
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP-1 O
proteins O
did O
so O
much O
less O
than O
Tax O
, O
indicating O
that O
the O
activation O
of O
the O
AP-1 O
site O
by O
Tax O
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP-1 B
mRNA I
. O

MATERIALS O
AND O
METHODS O
: O
Human B
p45 I
mRNAs I
have O
two O
alternative O
isoforms O
, O
aNF-E2 B
and O
fNF-E2 B
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative O
promoters O
. O

fNF-E2 B
mRNA I
was O
found O
to O
be O
more O
abundant O
in O
erythroid O
cells O
than O
megakaryocytic O
cells O
at O
day O
7 O
of O
culture O
. O

Although O
both O
isomers O
were O
expressed O
in O
human O
erythroid-megakaryocytic O
cell O
lines O
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF-E2 B
, O
suggesting O
that O
fNF-E2 O
promoter O
is O
more O
erythroid O
specific O
. O

Supporting O
this O
notion O
, O
TNF-alpha O
-induced O
upregulation O
of O
GM-CSF B
mRNA I
levels O
and O
protein O
secretion O
in O
the O
TNF-alpha O
-proliferative O
, O
but O
not O
in O
the O
TNF-alpha-apoptotic O
cell O
lines O
. O

While O
mitogenic O
doses O
of O
Fab'2 O
anti-Ig O
induce O
large O
and O
rapid O
increases O
in O
Egr-1 O
expression O
, O
IgG O
anti-Ig O
results O
in O
smaller O
increases O
in O
Egr-1 B
mRNA I
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab'2 O
anti-Ig O
. O

No O
corresponding O
increases O
in O
Egr-1 B
mRNA I
levels O
are O
observed O
when O
IL-4 O
is O
added O
. O

Therefore O
, O
IL-4 O
overcomes O
Fc O
receptor-mediated O
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr-1 B
mRNA I
induction O
, O
as O
demonstrated O
earlier O
for O
c-myc B
mRNA I
in O
this O
system O
. O

In O
this O
paper O
, O
TNF-alpha B
mRNA I
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine O
T O
cell O
clone O
by O
stimulation O
with O
T O
cell O
receptor O
( O
TCR O
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

Induction O
of O
the O
inducible O
nuclear O
complexes O
is O
rapid O
, O
independent O
of O
protein O
synthesis O
, O
and O
blocked O
by O
CsA O
, O
and O
thus O
, O
exactly O
parallels O
the O
induction O
of O
TNF-alpha B
mRNA I
by O
TCR O
ligands O
or O
by O
calcium O
ionophore O
. O

In O
contrast O
, O
when O
HL-60 O
cells O
were O
treated O
with O
retinoic O
acid O
, O
a O
granulocytic O
differentiation O
inducer O
, O
no O
enhanced O
AP-1 O
binding O
activity O
was O
observed O
, O
and O
only O
a O
weak O
increase O
in O
jun B
D I
mRNA I
level O
was O
detected O
. O

The O
timing O
and O
pattern O
of O
expression O
of O
these O
different O
mRNAs B
during O
avian O
erythroid O
development O
and O
differentiation O
suggests O
that O
temporally O
regulated O
changes O
in O
GATA O
factor O
expression O
are O
required O
for O
vertebrate O
hematopoiesis O
. O

Inhibition O
of O
protein O
kinase O
A O
by O
H89 O
reduced O
IL-6 B
mRNA I
levels O
but O
did O
not O
detectably O
change O
IL-1 O
beta O
or O
TNF-alpha O
mRNA O
levels O
. O

In O
contrast O
, O
LPS O
did O
not O
increase O
leukemia B
inhibitory I
factor I
mRNA I
, O
which O
was O
constitutively O
expressed O
and O
not O
significantly O
reduced O
by O
these O
inhibitors O
. O

In O
addition O
to O
cytokine B
mRNA I
levels O
, O
LPS-induced O
IL-6 O
protein O
synthesis O
and O
IL-6 O
bioactivity O
were O
also O
reduced O
to O
baseline O
levels O
by O
the O
PTK O
inhibitors O
herbimycin O
A O
and O
genistein O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear O
factor-kappa O
B O
( O
NF-kappa O
B O
) O
, O
which O
is O
a O
transcription O
factor O
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL-6 O
and O
TNF-alpha O
. O

